NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Descending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00409-4755-11 | 00409-4755 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Oct. 24, 2014 | Oct. 16, 2017 | In Use |
00409-4755-12 | 00409-4755 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Oct. 24, 2014 | Oct. 16, 2017 | In Use |
00409-4755-18 | 00409-4755 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Oct. 24, 2014 | In Use | |
00641-6078-01 | 00641-6078 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | In Use | |
00641-6078-25 | 00641-6078 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | In Use | |
00641-6080-01 | 00641-6080 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | In Use | |
00641-6080-25 | 00641-6080 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | In Use | |
59923-0701-00 | 59923-0701 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 19, 2014 | In Use | |
59923-0701-25 | 59923-0701 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 19, 2014 | In Use | |
70518-2650-00 | 70518-2650 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | March 25, 2020 | In Use | |
23155-0168-31 | 23155-0168 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Dec. 13, 2012 | Aug. 12, 2020 | In Use |
23155-0196-31 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-41 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-42 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | In Use | |
23155-0196-43 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 18, 2013 | July 31, 2020 | In Use |
23155-0377-31 | 23155-0377 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 24, 2014 | Oct. 11, 2019 | In Use |
23155-0378-31 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
23155-0378-41 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
23155-0378-42 | 23155-0378 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 19, 2014 | Oct. 11, 2019 | In Use |
25021-0782-20 | 25021-0782 | ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 30, 2012 | Nov. 30, 2021 | No Longer Used |
36000-0013-01 | 36000-0013 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | March 13, 2013 | March 9, 2020 | In Use |
50090-2342-00 | 50090-2342 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | April 6, 2016 | Sept. 30, 2018 | In Use |
55154-2873-05 | 55154-2873 | Ondansetron Hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 19, 2010 | March 28, 2018 | No Longer Used |
66733-0948-23 | 66733-0948 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Feb. 12, 2004 | In Use | |
66733-0958-23 | 66733-0958 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct. 2, 2007 | In Use |
Found 10,000 results in 11 milliseconds — Export these results